Brief: Personalis, ABRCC, and Criterium Announce Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
02/05/2023 13:46
May 2 (Reuters) - Personalis Inc PSNL.O :
* PERSONALIS, ABRCC, AND CRITERIUM ANNOUNCE MAJOR
PROSPECTIVE
CLINICAL TRIAL FOR RESIDUAL AND RECURRENT DISEASE DETECTION IN
TRIPLE NEGATIVE BREAST CANCER
Source text for Eikon: ID:nBw3H9KFJa
Further company coverage: PSNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Personalis
See all newsBrief: Personalis - Announces Commercial Launch Of Real-Time Variant Tracker In Next Personal Mrd Test
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
Personalis slips as BTIG downgrades, sees no rival bid for Tempus deal
Brief: Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP
Personalis, Inc. reports results for the quarter ended June 30 - Earnings Summary